Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients
American Journal of Blood Research · 2026
DOI: 10.62347/vckt6128 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Blood Research, 2026. Verfasst von Nidhi Dhariwal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre New Chandigarh, Punjab, India. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Oncology, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre New Chandigarh, Punjab, India.
- Division of Pediatric Oncology, Department of Medical Oncology, Tata Memorial Hospital Mumbai, Maharashtra, India.
Zitieren
APA
Dhariwal, N., & Srinivasan, S. (2026). Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. American Journal of Blood Research. https://doi.org/10.62347/vckt6128
Vancouver
Dhariwal N, Srinivasan S. Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. American Journal of Blood Research. 2026. doi:10.62347/vckt6128
BibTeX
@article{Dhariwal2026,
author = {Dhariwal, Nidhi and Srinivasan, Shyam},
title = {Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients},
journal = {American Journal of Blood Research},
year = {2026},
doi = {10.62347/vckt6128}
}
EUVIMED